Table 1

Clinical course and bacteriology

CasePresentedAge (months), sexDiseaseLowest eGFR
(mL/min/1.73 m2)
DATAdmission duration (days)Renal replacement therapy, duration (days)SerotypeVaccineVaccine failure
1December 200112, FMeningitis, bacteraemia9Negative18PD, 714NilNo
2May 200720, FPneumonia/empyema10Positive (C3d)12PD, 73PCV7No
3April 200919, FPneumonia/empyema, bacteraemia5Positive (IgG, C3d)36PD, 42819APCV7No
4March 201011, MPneumonia/empyema8Positive (IgG, C3d)26PD, 1919APCV7No
5August 201112, MPneumonia/empyema15Positive (IgG, C3d)15PD, 219APCV7No
6September 201212, MPneumonia/empyema1917Nil19APCV13Yes
7November 201317, MPneumonia, bacteraemia35Negative9Nil7FPCV13Yes
8September 201412, FPneumonia/empyema, bacteraemia6Negative25PD, 2319ANilNo
9April 201611, MPneumonia/empyema2015CVVH, 23PCV13Yes
10April 20167, FPresumed meningitis, bacteraemia10Negative19PD, 410APCV13No
11May 201618, MPneumonia/empyema, bacteraemia15Negative14CVVH, 419APCV13Yes
  • C3d, complement factor 3d; CVVH, continuous veno-venous haemofiltration; DAT, direct antiglobulin test; eGFR, estimated glomerular filtration rate; IgG, immunoglobulin G; PCV, pneumococcal conjugate vaccine (7-valent or 13-valent); PD, peritoneal dialysis.